Based on the analysis of data from previous population base studies (i.e., the Copenhagen General Population Study (CGPS), the Copenhagen City Heart Study (CHS), and the Copenhagen Ischemic Heart Disease Study (CIHDS)), an Lp(a) level reduction of 50 mg/dL (105 nmol/L) in the short term (i.e., 5 years) may be needed to decrease CV risk by 20% in secondary prevention settings [64]. The gene discussed is LPA; the disease is coronary artery disorder.